Evaluating DHA Supplementation in Alzheimer's Patients
Author Information
Author(s): Ogunade Temi, Yassine Hussein, Duro Marlon Vincent
Primary Institution: USC Leonard Davis School of Gerontology, Los Angeles, California, United States
Hypothesis
APOE4 is associated with greater cPLA2 activity in cerebrospinal fluid (CSF), resulting in a lower increase in CSF DHA levels after supplementation.
Conclusion
The study aims to provide insights on how APOE4 complicates responses to DHA supplementation in Alzheimer's patients.
Supporting Evidence
- Alzheimer's disease is characterized by cognitive decline and neuroinflammation.
- APOE4 is the greatest genetic risk factor for late-onset Alzheimer's disease.
- Most studies on omega-3 supplements show inconsistent results in APOE4 carriers.
Takeaway
This study looks at how a specific gene might affect the way a brain supplement works in people at risk for Alzheimer's.
Methodology
Randomized, double-blind study measuring cPLA2 activity in CSF samples from participants.
Participant Demographics
368 cognitively unimpaired adults with cardiovascular risk factors for dementia, including 184 APOE4 carriers and 184 non-APOE4 carriers.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website